Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 3/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247809 | 1.00 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18885183 | 0.84 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL25974967 | 0.83 | MC4R (0.41) | TSHRCES2CES1RORCPKM | |
| SCHEMBL12686634 | 0.83 | MC4R (0.41) | TSHRCES2CES1RORCPKM | |
| SCHEMBL12686652 | 0.83 | MC4R (0.41) | TSHRCES2CES1RORCPKM | |
| SCHEMBL19620840 | 0.82 | SLC6A4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12172686 | 0.82 | TSHR (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18885180 | 0.82 | RORC (0.58) | TSHRRORCCA3CA6CA5A | |
| SCHEMBL22271746 | 0.82 | TSHR (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL26081489 | 0.82 | TSHR (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| EP-3162801-B1 | SALT OF HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2020-07-02 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2020-04-07 | — | — | US | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| EP-1439157-B1 | Method for producing Suzuki coupling compound catalysed by a nickel compound | SUMITOMO CHEMICAL CO (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7238832-B2 | Production method of a coupling compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-07-03 | — | — | US | disclosed |
| US-7217677-B2 | Method for producing coupling compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060281925-A1 | METHOD FOR PRODUCING COUPLING COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1449580-B1 | Production method of a cross-coupling compound from an alkyl halide and an organoboron compound | SUMITOMO CHEMICAL CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20040167364-A1 | Production method of a coupling compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-26 | — | — | US | disclosed |
| EP-1449580-A1 | Production method of a cross-coupling compound from an alkyl halide and an organoboron compound | Sumitomo Chemical Co.,Ltd. (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20040161404-A1 | Method for producing coupling compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-08-19 | — | — | US | disclosed |
| EP-1439157-A2 | Method for producing Suzuki coupling compound catalysed by a nickel compound | Sumitomo Chemical Co.,Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207726-A1 | INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORA, RORC, RORB | PSEN1 1936/4885PSEN2 2125/4885APH1B 3042/4885 |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | PSEN1 928/4885PSEN2 1612/4885APH1B 1737/4885 |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | PSEN1 1181/4885PSEN2 1899/4885APH1B 2025/4885 |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | PSEN1 2978/4885PSEN2 3296/4885APH1B 2699/4885 |
| US-20040167364-A1 | Production method of a coupling compound | PYM1, BRIX1, CXCR1 | PSEN1 2451/4885PSEN2 2180/4885APH1B 3028/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | PSEN1 157/4885PSEN2 138/4885APH1B 918/4885 |
| US-20060281925-A1 | METHOD FOR PRODUCING COUPLING COMPOUND | RPL22, CYP4A22, PYM1 | PSEN1 2264/4885PSEN2 1010/4885APH1B 2820/4885 |
| US-20080113985-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | PSEN1 2580/4885PSEN2 3214/4885APH1B 1096/4885 |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | LPAR3, LPAR1, LPAR2 | PSEN1 4737/4885PSEN2 4758/4885APH1B 2774/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | PSEN1 399/4885PSEN2 223/4885APH1B 1548/4885 |
| US-20040161404-A1 | Method for producing coupling compound | PYM1, MALT1, BET1 | PSEN1 2599/4885PSEN2 2467/4885APH1B 2362/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | PSEN1 2978/4885PSEN2 3296/4885APH1B 2699/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | PSEN1 1226/4885PSEN2 1848/4885APH1B 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.